Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

Novo Nordisk's Alzheimer's trial really is like a lottery ticket. If it wins, the company gains a transformational new market and billions in revenue. If it loses, the core diabetes and obesity ...

The US pharmaceutical company Eli Lilly has met with the Department of Enterprise to express concerns about planned changes to the patent law in Europe. The multinational, which employs 3,500 people ...

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 ...

The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost ...

Basketball legend, entrepreneur and entertainer Shaquille O'Neal partners with Lilly to shine a spotlight on moderate-to-severe obstructive sleep apnea (OSA), encouraging ...

The US FDA has granted clearance for Roche's Elecsys pTau181 test for the preliminary evaluation of Alzheimer's disease.

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...

Until recently, GLP -1s, a powerful new class of weight-loss drugs, were confined mostly to rich countries. Yet the World ...

Indianapolis-based Eli Lilly and Co. on Friday announced it is acquiring California-based Adverum Biotechnologies, a developer of gene therapies focused on age-related vision loss. Adverum is ...